Navigation Links
Biosystems International Merges With Microbiochips

Biosystems International Merges With Microbiochips -- PARIS, September 13, 2010 /PRNewswire/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Medical Pharmaceuticals, Pharmaceuticals, Acquisitions, Mergers and Takeovers Click to view news release full screen  

Biosystems International Merges With Microbiochips


PARIS, September 13, 2010 /PRNewswire/ -- Biosystems International (BSI), a biotechnology company specializing in the discovery of novel monoclonal antibody based diagnostics, announces its merger with the company MicroBioChips (MBC) by contribution of assets.

Advantages of the merger

Following a successful partnership to develop monoclonal antibody microarrays, in which BSI provided the antibodies and MBC produced and commercialized the microarrays, the two companies have decided to solidify their collaboration by merging their activities. By combining their collective expertise the resulting company will optimize the production and sales of microarrays and related services and accelerate the development of diagnostic tests by BSI. In addition, the merger will lead to significant commercial, administrative and financial synergies.

"The merger of BSI and MBC is not limited to synergies and cost savings. Our complimentary business cultures will profoundly change our way of doing business, reducing the time to market for our diagnostics including in the short-term our test for lung cancer which is in late development," said Jean Pierre Tirouflet, President of Biosystems International.

Conditions of the merger

The partial transfer of assets of MBC to BSI was approved in Shareholders meetings held by the two companies at the end of July, 2010. Preceding the transaction, the two companies realized a capital increase of 2 125 000 EUR ($2 750 000) for BSI and 225 000 EUR ($300 000) for MBC assuring the new merged company sufficient capital for future development.


Microbiochips is a company specialized in the production of protein and antibody arrays and related services. Certified ISO 9001, the company excels in the custom production and processing of protein microarrays, bioinformatics and data analysis for academic and industrial clients including major pharmaceutical companies.

About Biosystems International

Biosystems International (BSI) is a biotechnology company specializing in the discovery and development of novel diagnostics for diseases with critical unmet needs. Using our proprietary monoclonal antibody proteomics process BSI rapidly discovers novel biomarkers and corresponding antibodies in a single step.

The company is currently focused on the discovery and development of diagnostic tests in the areas of cancer and chronic diseases as well as the development and commercialization of antibody arrays for plasma proteome profiling.

Safe Harbor Statement

Except for historical information contained herein, statements made in this release that would constitute forward-looking statements may involve certain risks and uncertainties. All forward-looking statements made in this release are based on currently available information and the company assumes no responsibility to update any such forward looking statements.

Contacts - Elisabeth Rocolle-Teyssier, CFO - William Hempel, Director of Scientific Communication - Tel : +33-1-60-87-89-75 -

SOURCE BioSystems International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NEXUS Biosystems Completes Acquisition of REMP Sample Management Business From Tecan Group
2. NEXUS Biosystems Acquires Tecan Groups REMP Sample Management Business
3. Incept BioSystems Initiates First Human Clinical Trial of its SMART Embryo Culture System for In Vitro Fertilization (IVF)
4. Medizone International Files For Additional Bio-Terrorism Countermeasures Patent Protection
5. International Isotopes Inc. Announces Completion of a Licensing and Permitting Assistance Agreement with URENCO USA
6. Dyadic International and EnGen Bio to Present at Rodman & Renshaw Annual Global Investment Conference
7. Dyadic International Raises Additional $1 Million to Complete $4 Million Convertible Note Offering
8. /C O R R E C T I O N - Mindray Medical International Limited /
9. Ellman International Announces Executive Team Hire
10. Yongye International Announces RMB 400 Million Revolving Credit Facilities
11. Yongye International to Present at 2010 ROTH Fall Conference
Post Your Comments:
(Date:10/11/2017)... 11, 2017  BioPharmX Corporation (NYSE MKT: BPMX) researchers ... an innovative way to use nonlinear optical imaging to ... new drugs. ... will show how researchers from BioPharmX and the Wellman ... used a suite of imaging techniques in what is ...
(Date:10/11/2017)... , Oct. 11, 2017  True Health, ... has amplified its effort during National Breast Cancer ... hereditary cancer risks. ... Clinical Oncology calculated that more than 10 million ... inherited mutations in BRCA1 or BRCA2 and have not ...
(Date:10/10/2017)... received FDA 510(k) clearance in May 2017 for its highly anticipated ... for endoscopy environments. An innovative secondary monitor solution, ZeroWire Mobile ... the improvement of patient outcomes, procedural efficiency, and the lowering of ... ... By ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and ... explains one of the most popular and least understood books in the Holy Scriptures, ... puzzling descriptions that have baffled scholars for centuries. Many have tossed it off as ...
(Date:10/13/2017)... ... 2017 , ... “America On The Brink”: the Christian history of the United ... the creation of published author, William Nowers. Captain Nowers and his wife, Millie, ... spent thirty years in the Navy. Following his career as a naval aviator ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the ... – Miles by Moonlight to raise money for the American Heart Association Heart Walk. ... , Teams will work together to keep their treadmills moving for 5 hours. Treadmills ...
Breaking Medicine News(10 mins):